Donor Site Complication Clinical Trial
Official title:
A Phase I/II Study to Evaluate the Safety and Efficacy of TWB-103 in Adult Patients With Split-Thickness Skin Graft Donor Site Wounds (DSW)
Primary objective: 1. To evaluate the safety of TWB-103 in split-thickness skin graft donor site wounds (DSW) for Phase I in terms of Incidence of treatment-related AEs and SAEs (including infections and bleeding) 2. To evaluate the efficacy for Phase I+II of TWB-103 in split-thickness skin graft donor site wounds (DSW) in terms of The healing time from DSW creation to 100% re-epithelialization Secondary objective: 1. To evaluate the efficacy of TWB-103 in split-thickness skin graft donor site wounds (DSW) in secondary efficacy endpoints 2. To evaluate the safety of TWB-103 in split-thickness skin graft donor site wounds (DSW) in secondary safety endpoints
The study was designed to evaluate the safety and efficacy of the TWB-103 in adult subjects with split-thickness skin graft donor site wounds (DSW). In Phase I proportion, eligible subjects were recruited sequentially with one week staggering of treatment. Eligible subjects were randomized into TWB-103 or Placebo groups in a 1:1 ratio. Phase I was planned to recruit 3 evaluable subjects each in TWB-103 and Placebo groups. Evaluable subjects in Phase I were (1) he/she who received at least one dose and had follow-up evaluation at least 14 days after the first dose or (2) he/she who received at least one dose and had early withdrawn due to safety reasons before Day 28. When all of those 6 evaluable subjects completed the planned treatment period (14 days or till first 100% re-epithelialization, which came first), the recruitment was temporarily stopped for 14 days for safety observation. The safety data before and on Day 28 Visit were reviewed by the sponsor and the principal investigator. If no safety issue was decided, the study would enter Phase II portion and eligible subjects would be randomized into a 1:1 ratio into one of the TWB-103 and Placebo groups. The dosing regimen designed in Phase II portion was the same as it was designed in Phase I portion. Subjects were instructed to attend scheduled visits at Screening, Day 0 (treatment start the day), Day 3, Day 7, Day 10, and Day 14 (end of treatment). All subjects were scheduled to attend a follow-up visit on Day 28 to evaluate the status of the target wound and then enter a 360-day follow-up phase. During the 360-day follow-up, four follow-up visits were scheduled at 90±14 days, 180±14 days, 270±14 days, and 360±14 days following the subject's Day 28 visit (if no Day 42 visit) or Day 42 visit. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03663036 -
Arthroscopic Superior Capsular Reconstruction With Fascia Lata Autograft - Survivorship of the Autograft Analysis
|
N/A | |
Completed |
NCT01670201 -
An Investigation to Evaluate a New Donor Site Dressing in Surgical Burn Patients
|
N/A | |
Completed |
NCT04422925 -
s100β, NSE n GFAP in Living Donor Hepatectomy and Delirium
|
||
Recruiting |
NCT06030791 -
BTB Graft Harvest and Donor Site Morbidity After ACL Reconstruction
|
||
Completed |
NCT04050124 -
Impact of Prisma on Donor Site Pain
|
N/A | |
Not yet recruiting |
NCT04997863 -
Clinical Efficacy and Safety of Sericin Hydrogel Sheet Impregnated With Bird's Nest Extract
|
N/A | |
Not yet recruiting |
NCT03850119 -
Nanofat on Wound Healing and Scar Formation
|
N/A | |
Completed |
NCT04490213 -
Scarring At Donor Sites After Split-Thickness Skin Graft.
|
||
Terminated |
NCT03992820 -
Transcutaneous Electrical Nerve Stimulation for Local Anaesthesia
|
N/A | |
Completed |
NCT04403503 -
The Influence of Tissue Adhesive to Palatal Donor Site Healing.
|
N/A | |
Completed |
NCT03209167 -
Comparing Patient Satisfaction of the Abdomen After DIEAP Procedure and Conventional Abdominoplasty
|
N/A | |
Recruiting |
NCT04743375 -
Clinical Efficacy of Silk Sericin Dressing With Collagen for Split-thickness Skin Graft Donor Site Treatment
|
N/A | |
Recruiting |
NCT05740033 -
Radial Forearm Donor Site Closure
|
N/A | |
Recruiting |
NCT04186273 -
Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2.
|
Phase 2 | |
Completed |
NCT04692961 -
Change in the Lower Leg Muscle Stiffness Following Peroneal Artery-based Flap
|
N/A | |
Completed |
NCT06044519 -
A Single Center Trial of Donor Site Wound Dressings After Split Thickness Skin Grafting.
|
Phase 4 | |
Completed |
NCT04867070 -
Pain Management in Laparoscopic Living-donor Nephrectomy: The Impact of Erector Spinae Plane Block (ESPB) on Perioperative Period
|
N/A | |
Terminated |
NCT02671344 -
Determining the Genetic Profile in Semen Donors With Pregnancy, Donor Versus no Pregnancy Obtained in TRA
|